According to a local health chief, people in the UK could actually get vaccines against coronavirus from December 9th.
The NHS in Nottingham is preparing to start delivering shocks in less than two weeks when given the go-ahead from drug regulators.
So far, none have been approved for public use – but the MHRA watchdog is already reviewing one from Pfizer and will be considering competing candidates from AstraZeneca and Moderna in the coming weeks.
Ministers wanted the country to be operational by December 1st so that as many people as possible could be vaccinated before the New Year.
With a license pending, the chances of people actually being invited to a clinic in the next five days are getting smaller – although the UK may well be on track to be the first country in the world to start vaccinating, believe government sources.
Nursing home residents and workers are a priority for a vaccine as the disease is deadliest for the elderly and the army is said to be drafted to carry out the mammoth effort.
Speaking at a council meeting in Nottinghamshire earlier this week, one of the area's top health leaders said, "We want to go live by Wednesday 9th December if a vaccine is available," Nottinghamshire reported Live.
Hoping to get the UK and the world out of a seemingly endless cycle of lockdowns and social distancing depends on Covid shocks being successful and people volunteering for them.
No vaccines have been approved for the public yet, but the UK drug watchdog is evaluating a vaccine made by Pfizer and could make a decision in a matter of days (Image: A vial of a vaccine from AstraZeneca which is also on track to be approved by the end of the year)
The vaccination schedule was set by Sarah Carter, Executive Executive Incident Director at the Nottingham and Nottinghamshire Clinical Commissioning Group (CCG).
The CCG leads all local NHS services in the area and said that volunteers and additional staff have already been hired to deliver vaccines.
Ms. Carter said, “We aim to have everything in place by December 1st as mandated by national governance and we believe we want to go live by Wednesday December 9th and the entire system is ready to move this forward. & # 39;
She added, "We have been working to prepare to carry out what is arguably the most unprecedented vaccination program we have ever seen."
The Ministry of Health has not confirmed a national timeframe for possible vaccinations if a sting has been approved by the MHRA.
The program started as quickly as possible and adhered to "robust standards". A spokesperson said, "We will release more details about our deployment plans in due course."
Health Secretary Matt Hancock urged the NHS to be ready for launch on December 1, but the program cannot be launched until the MHRA, the drug and health products regulator, decides that a vaccine is safe enough and good enough to be administered to the public.
This rigorous scientific process began months ago and is expected to be completed in the coming days or weeks.
So far, the signs for Pfizer and BioNTech's vaccine candidate have been promising after clinical studies showed that it offers 95 percent protection against Covid-19 and does not cause major side effects.
ASTRAZENECA BOSS rejects claims CLINICAL PROCESS RESULT IS & # 39; SHAKY & # 39;
An AstraZeneca boss has dismissed criticism of Oxford University's coronavirus vaccine, insisting that it hit the “approval threshold” after experts raised concerns about the “shaky science” behind it.
Hopes of an end to the pandemic grew on Monday when Oxford scientists announced that the sting made by Cambridge-based AstraZeneca could block up to 90 percent of Covid-19 infections.
The figure, which critics said is based on patched data from 2,300 volunteers under the age of 55 who were accidentally given a half and then a full dose, has been questioned by experts because of the small number of people tested.
The dosage error was only discovered when it was found that some participants had fewer side effects.
In Moderna and Pfizer's vaccine trials, which are also believed to be at least 90 percent effective, around 10,000 volunteers received the same doses.
Dr. Mene Pangalos, Executive Vice President of Research at AstraZeneca, has now tried to fend off criticism and insist: "I'm not going to pretend it's not an interesting result because it is – but I definitely don't get it and I do it not." I don't think either of us do.
& # 39; The error is actually irrelevant. No matter how you cut the data – even if you just believe in the full-dose and full-dose data … we still have an efficacy that meets the thresholds for approval with a vaccine that is over 60 percent effective. & # 39;
The World Health Organization has set a target of 50 percent effectiveness for a Covid-19 shock, a threshold that Oxford exceeded after its shock was 60 percent effective in people given two full doses.
A government source reportedly told The Sun that the UK has a 50/50 chance of becoming the first country to receive a Covid vaccine and that it could do so as soon as next week.
"It looks pretty accurate and we could make a decision as early as next week," said the unnamed source.
"If so, there's a 50/50 chance we'll be the first country in the world to approve a vaccine for launch."
If vaccines are approved by Christmas, the UK could get enough doses to vaccinate 10 million people or more before the end of 2020.
This would mean the most vulnerable people in society could be protected from Covid-19 as early as February – the bumps in studies require two doses a month apart.
Mr Hancock said this month, "We don't yet know if or when a vaccine will be approved, but I have mandated the NHS to be ready from any date starting December 1st."
At a meeting with Parliament's Health and Social Committee this week, Mr Hancock was optimistic that a vaccine could bring the country back to normal within months.
"After Easter, we think we'll get back to normal," he said.
“Well, there are some things that are 'no regrets', right? Wash your hands more and some parts of social distancing have no regrets, which I think is becoming commonplace.
"But these harmful social distancing measures, which have diminished, whether economic or social harm to our well-being, I hope we can lift them after Easter when these two vaccines are approved by the regulator, which of course is independent." Decision for the MHRA. & # 39;
Leaked NHS plans show that once the vaccination program is launched, it will likely move in a flash.
A document published in the Health Service Journal last week showed that if A vaccine is approved as scheduled. The first doses are expected to be available next month and will be given first to people in nursing homes and the caregivers who care for them.
The shocks are then prioritized according to age and general health, with healthy under 50s coming last.
But even those in the lowest risk group can potentially start vaccinating in just two months, if everything goes according to plan.
The files say any deadlines set for vaccines depend on the arrival of supplies – with up to seven million doses expected in the next month – and are based on NHS proposals to create huge GP facilities to dispense the shots.
It has been reported that the NHS plans to deliver 1 million Covid-19 vaccines a day by early 2021.
Regulators are expected to approve at least one vaccine by the end of the year. Currently, Pfizer will be the first to be licensed with a dose of £ 15 per dose.
The UK has ordered 40 million doses of Pfizer's vaccine – the first batch is expected to arrive next month – and five million modernas – due next spring.
There's also an order for up to 100 million vials of Oxford's candidates that scientists say will complete clinical trials by Christmas and could be ready for use for the 19 million doses in 2020.
The leaked plans suggest vaccines could be made available to all adults in the UK by the end of January, but the bulk of 18- to 50-year-olds would likely be vaccinated in March with the aim of ensuring that anyone in the UK who has one Stitch wishes he received a vaccine April.
HOW DO THE OXFORD, MODERNA AND PFIZER / BIONTECH Vaccines compare?
Moderna and Pfizer / BioNTech have both released interim clinical trial results for their end-stage vaccines, both of which indicate that they are extremely effective.
Oxford University has published the results of its second phase, showing that the sting induces an immune response and is safe to use. It's not yet clear how well it protects against coronavirus in the real world.
How to Compare:
PFIZER (US) & BIONTECH (DE)
mRNA vaccine – Genetic material from the coronavirus is injected to stimulate the immune system to make "spike" proteins and learn how to attack them.
mRNA vaccine – both Moderna, Pfizer and BioNTech vaccines work the same way.
Recombinant Viral Vector Vaccine – a harmless chimpanzee cold virus was engineered to produce the "spike" proteins and look like the coronavirus.
94.5% effective (90 positive in the placebo group, 5 positive in the vaccine group).
95% effective (160 positive in the placebo group, 8 positive in the vaccine group).
62% – 90% effective, depending on the dosage.
Moderna confirmed that countries placing smaller orders, such as the UK's five million cans, will pay between £ 24 and £ 28 per dose. The US has secured 100 million doses for $ 1.525 billion (£ 1.16 billion), suggesting it will cost $ 15.25 (11.57 pounds) per dose.
The US pays $ 1.95 billion (£ 1.48 billion) for the first 100 million doses, which is the equivalent of $ 19.50 (£ 14.80) per dose.
Estimated to cost £ 2.23 per dose. The UK's full 100 million dose supply could add up to just £ 223 million.
The UK has ordered five million cans that will be available from March 2021. Moderna will produce 20 million cans this year, which is expected to remain in the US.
The UK has already ordered 40 million cans, 10 million of which could be available in 2020. The first vaccinations are expected in December.
The UK has already ordered 100 million cans and is expected to come first to get the cans once approved.
What side effects does it cause?
Moderna said the vaccine was "generally safe and well tolerated". Most of the side effects were mild or moderate, but included pain, fatigue, and headache, which “generally” were short-lived.
Pfizer and BioNTech did not provide a breakdown of the side effects, but said the Data Monitoring Committee "did not report any serious safety concerns."
Oxford said there were no serious safety concerns. Mild side effects were relatively common in studies. Many participants reported that their arm hurt after the shock and that they later suffered from headache, fatigue, or muscle pain.
(tagsToTranslate) Dailymail (t) News (t) Coronavirus (t) Pfizer (t) AstraZeneca (t) NHS